l General Information |
Product Name | Efinaconazole |
General description | Efinaconazole is an inhibitor of 14 alpha-demethylase which is involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes. |
Synonym | KP-103; (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol |
Purity | ≥99.0%(HPLC) | CAS Number | 164650-44-6 |
Formula | C18H22F2N4O | Molecular Weight | 348.39 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White to beige Solid |
Solubility(25°C) | DMSO | ≥45mg/ml |
Ethanol | ≥45mg/ml |
Water | Very slightly soluble |
l Biological Information |
Biochem/Physiol
Actions | Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis. It was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. |
l Storage |
Storage temp. | -20°C |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
